Increasing technological advancements facilitating the production of novel products is expected to drive growth of the Recombinant DNA Technology Market

The market is predicted to increase due to great advancements paired with a wide range of applications to treat life-threatening human diseases such as cancer, diabetes, and infectious diseases. According to the Global Diabetes Community, diabetes affects an estimated 422 million adults worldwide in 2017, with the number anticipated to rise to 642 million by 2040. According to the World Health Organization (WHO), diabetes is responsible for 1.5 million fatalities while hyperglycemia, or high blood glucose levels, is responsible for 2.2 million deaths. Advances in recombinant technologies have aided the development of long-acting therapeutic proteins for drug development as well as the introduction of gene therapy, a novel molecular medicine, all of which have aided the growth of the recombinant DNA technology market by improving the treatment of genetic diseases. Furthermore, scientists may utilise the breakthrough gene editing technique CRISPR to target the death of aberrant genes in human cells, giving them a strong tool to make precise alterations to DNA in microorganisms, plants, mice, dogs, and human cells.

 

Recombinant DNA Technology Market

Recombinant DNA technology has also led to the development of high-yielding, insect- and heat-resistant crop types such as soyabean, cotton, rice, and maize that require less herbicide use, cutting agricultural costs. Vitamin A-enriched (golden) rice was also created using rDNA technology to combat disorders like Vitamin A deficiency (VAD), proving to be a breakthrough in the fight against malnutrition. According to the Golden Rice Humanitarian Board, VAD afflicted more than 140 million pre-school children in 118 countries in 2016, as well as more than seven million pregnant mothers. In emerging economies, it is the major cause of childhood blindness.